These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 14634557)

  • 1. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine.
    Sobel JD; Chaim W; Nagappan V; Leaman D
    Am J Obstet Gynecol; 2003 Nov; 189(5):1297-300. PubMed ID: 14634557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections.
    White DJ; Habib AR; Vanthuyne A; Langford S; Symonds M
    Sex Transm Infect; 2001 Jun; 77(3):212-3. PubMed ID: 11402233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy.
    Sobel JD; Chaim W
    Clin Infect Dis; 1997 Apr; 24(4):649-52. PubMed ID: 9145739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terconazole cream for non-Candida albicans fungal vaginitis: results of a retrospective analysis.
    Sood G; Nyirjesy P; Weitz MV; Chatwani A
    Infect Dis Obstet Gynecol; 2000; 8(5-6):240-3. PubMed ID: 11220485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis.
    Ray D; Goswami R; Banerjee U; Dadhwal V; Goswami D; Mandal P; Sreenivas V; Kochupillai N
    Diabetes Care; 2007 Feb; 30(2):312-7. PubMed ID: 17259500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence.
    Iavazzo C; Gkegkes ID; Zarkada IM; Falagas ME
    J Womens Health (Larchmt); 2011 Aug; 20(8):1245-55. PubMed ID: 21774671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boric acid for refractory Candida glabrata vaginitis.
    Dhingra S; Roseblade CK
    J Obstet Gynaecol; 2006 Aug; 26(6):584. PubMed ID: 17000521
    [No Abstract]   [Full Text] [Related]  

  • 8. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).
    Mendling W; Brasch J; Cornely OA; Effendy I; Friese K; Ginter-Hanselmayer G; Hof H; Mayser P; Mylonas I; Ruhnke M; Schaller M; Weissenbacher ER
    Mycoses; 2015 Mar; 58 Suppl 1():1-15. PubMed ID: 25711406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and management of non-albicans vaginal candidiasis.
    Hettiarachchi N; Ashbee HR; Wilson JD
    Sex Transm Infect; 2010 Apr; 86(2):99-100. PubMed ID: 20332368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Candida glabrata using topical amphotericin B and flucytosine.
    Shann S; Wilson J
    Sex Transm Infect; 2003 Jun; 79(3):265-6. PubMed ID: 12794227
    [No Abstract]   [Full Text] [Related]  

  • 11. Prolonged (3-month) mycological cure rate after boric acid suppositories in diabetic women with vulvovaginal candidiasis.
    Ray D; Goswami R; Dadhwal V; Goswami D; Banerjee U; Kochupillai N
    J Infect; 2007 Oct; 55(4):374-7. PubMed ID: 17692922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents.
    Redondo-Lopez V; Lynch M; Schmitt C; Cook R; Sobel JD
    Obstet Gynecol; 1990 Oct; 76(4):651-5. PubMed ID: 2216197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-albicans Candida Vulvovaginitis: Treatment Experience at a Tertiary Care Vaginitis Center.
    Powell AM; Gracely E; Nyirjesy P
    J Low Genit Tract Dis; 2016 Jan; 20(1):85-9. PubMed ID: 26083330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candida lusitaniae as an unusual cause of recurrent vaginitis and its successful treatment with intravaginal boric acid.
    Silverman NS; Morgan M; Nichols WS
    Infect Dis Obstet Gynecol; 2001; 9(4):245-7. PubMed ID: 11916183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yeast vaginitis during pregnancy: susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors.
    Kalkanci A; Güzel AB; Khalil II; Aydin M; Ilkit M; Kuştimur S
    Med Mycol; 2012 Aug; 50(6):585-93. PubMed ID: 22369624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case series of the management of symptomatic azole-resistant candida.
    Challenor R; Pinsent S; Ekanayaka R
    Int J STD AIDS; 2012 May; 23(5):375-6. PubMed ID: 22648899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal agents vs. boric acid for treating chronic mycotic vulvovaginitis.
    Jovanovic R; Congema E; Nguyen HT
    J Reprod Med; 1991 Aug; 36(8):593-7. PubMed ID: 1941801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boric Acid and Commercial Organoboron Products as Inhibitors of Drug-Resistant Candida albicans.
    Larsen B; Petrovic M; De Seta F
    Mycopathologia; 2018 Apr; 183(2):349-357. PubMed ID: 28993976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired Flucytosine Resistance during Combination Therapy with Caspofungin and Flucytosine for Candida glabrata Cystitis.
    Charlier C; El Sissy C; Bachelier-Bassi S; Scemla A; Quesne G; Sitterlé E; Legendre C; Lortholary O; Bougnoux ME
    Antimicrob Agents Chemother; 2016 Jan; 60(1):662-5. PubMed ID: 26525799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent vulvovaginal candidiasis.
    Ringdahl EN
    Mo Med; 2006; 103(2):165-8. PubMed ID: 16703718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.